mTORC Inhibitors as Broad-Spectrum Therapeutics for Age-Related Diseases

Walters, Hannah E., Cox, Lynne S.·2018·International Journal of Molecular Sciences
DOI 10.3390/ijms19082325

Cites (234)

Items 201–230 of 230

  1. Muscle wasting associated with the long-term use of mTOR inhibitors
    Bishal Gyawali, Tomoya Shimokata, Kazunori Honda, Chihiro Nakayama Kondoh, Naomi Hayashi, Yasushi Yoshino, Naoto Sassa, Yasuyuki Nakano, Momokazu Gotoh, Yukio Ando · 2016 · Molecular and Clinical Oncology
  2. mTORC2 Is Required for Rit-Mediated Oxidative Stress Resistance
    Weikang Cai, Douglas Andres · 2014 · PLoS ONE
  3. mTOR Activity Under Hypoxia
    Douangsone D. Vadysirisack, Leif William Ellisen · 2011 · Methods in molecular biology
  4. M(o)TOR of pseudo-hypoxic state in aging: Rapamycin to the rescue
    Olga V. Leontieva, Mikhail V. Blagosklonny · 2014 · Cell Cycle
  5. Quantitative Nuclear Proteomics Identifies mTOR Regulation of DNA Damage Response
    Sricharan Bandhakavi, Young Mi Kim, Seung‐Hyun Ro, Hongwei Xie, Getiria Onsongo, Chang Jun, Do‐Hyung Kim, Timothy J. Griffin · 2009 · Molecular & Cellular Proteomics
  6. Proteomic analysis reveals GIT1 as a novel mTOR complex component critical for mediating astrocyte survival
    Laura J. Smithson, David H. Gutmann · 2016 · Genes & Development
  7. Rapamycin and the transcription factor C/EBPβ as a switch in osteoclast differentiation: implications for lytic bone diseases
    Jeske J. Smink, Achim Leutz · 2009 · Journal of Molecular Medicine
  8. Interventions for preventing the progression of autosomal dominant polycystic kidney disease
    Davide Bolignano, Suetonia C. Palmer, Marinella Ruospo, Carmine Zoccali, Jonathan C. Craig, Giovanni FM Strippoli · 2015 · Cochrane Database of Systematic Reviews
  9. Efficacy of the oral mTORC1 inhibitor everolimus in relapsed or refractory indolent lymphoma
    N. Nora Bennani, Betsy R LaPlant, Stephen Maxted Ansell, Thomas Matthew Habermann, David James Inwards, Ivana N. Micallef, Patrick B. Johnston, Luis F. Porrata, Joseph P. Colgan, Svetomir N. Markovic et al. · 2017 · American Journal of Hematology
  10. Metformin reduces glucose intolerance caused by rapamycin treatment in genetically heterogeneous female mice
    R. Weiss, Elizabeth Fernández, Yuhong Liu, Randy Strong, Adam B. Salmon · 2018 · Aging
  11. Simultaneous induction and blockade of autophagy by a single agent
    Karolina Staniak, Magdalena Dudkowska, Anna M. Zawadzka, Mikolaj B. Ogrodnik, Andrzej Antoni Szczepankiewicz, Zbigniew Czarnocki, Ewa Sikora · 2018 · Cell Death and Disease
  12. Function of erbB receptors and DNA-PKcs on phosphorylation of cytoplasmic and nuclear Akt at S473 induced by erbB1 ligand and ionizing radiation
    Mahmoud Toulany, Tim-Andre Schickfluß, Kazi Riaz Fattah, Kyung Jong Lee, Benjamin P.C. Chen, Birgit Fehrenbacher, Martin Schaller, David J. Chen, H. Peter Rodemann · 2011 · Radiotherapy and Oncology
  13. Livers with Constitutive mTORC1 Activity Resist Steatosis Independent of Feedback Suppression of Akt
    Heidi L. Kenerson, Savitha Subramanian, Rebecca L. McIntyre, Machiko Kazami, Raymond S. W. Yeung · 2015 · PLoS ONE
  14. mTOR signaling plays a critical role in the defects observed in muscle-derived stem/progenitor cells isolated from a murine model of accelerated aging
    Koji Takayama, Yohei Kawakami, Mitra Lavasani, Xiaodong Mu, James H. Cummins, Takashi Yurube, Ryosuke Kuroda, Masahiro Kurosaka, Freddie H. Fu, Paul D. Robbins et al. · 2016 · Journal of Orthopaedic Research®
  15. Treatments to slow progression of autosomal dominant polycystic kidney disease: systematic review and meta‐analysis of randomized trials
    Thida Maung Myint, Gopi K. Rangan, Angela Claire Webster · 2014 · Nephrology
  16. A phase I–II study on the combination of rapamycin and short course radiotherapy in rectal cancer
    Jeroen Buijsen, Jørgen van den Bogaard, Barry Jutten, Eric H J Belgers, Meindert Nico Sosef, Jeroen W. A. Leijtens, Geerard L. Beets, Rob L. H. Jansen, Robert G. Riedl, Ruud Clarijs et al. · 2015 · Radiotherapy and Oncology
  17. Everolimus: a new hope for patients with breast cancer
    Mehmet Alı Nahıt Şendur, Nurullah Zengin, Sercan Aksoy, Kadri Altundağ · 2013 · Current Medical Research and Opinion
  18. Rapamycin-enhanced mitomycin C-induced apoptotic death is mediated through the S6K1–Bad–Bak pathway in peritoneal carcinomatosis
    Song, X, Dilly, A-K, Kim, S-Y, Choudry, H A, Lee, Y J · 2014 · Cell Death & Disease
  19. Functional Proteomics Identifies Acinus L as a Direct Insulin- and Amino Acid-Dependent Mammalian Target of Rapamycin Complex 1 (mTORC1) Substrate
    Jennifer Schwarz, Heike Wiese, Regine C. Tölle, Mostafa Zarei, Jörn Dengjel, Bettina Warscheid, Kathrin Thedieck · 2015 · Molecular & Cellular Proteomics
  20. Sirolimus for Treatment of Autosomal-Dominant Polycystic Kidney Disease: A Meta-Analysis of Randomized Controlled Trials
    Y.-M. Liu, Y.Q. Shao, Qiang He · 2014 · Transplantation Proceedings
  21. Profile of everolimus in the treatment of tuberous sclerosis complex: an evidence-based review of its place in therapy
    David Neal Franz, Jamie K. Capal · 2016 · Neuropsychiatric Disease and Treatment
  22. Author Correction: Disruption of the beclin 1–BCL2 autophagy regulatory complex promotes longevity in mice
    Álvaro F. Fernández, Salwa Sebti, Yongjie Wei, Zhongju Zou, Mingjun Shi, Kathryn L. McMillan, Congcong He, Tabitha C. Ting, Yang Liu, Wei‐Chung Chiang et al. · 2018 · Nature
  23. Bromodomain-containing protein 2 induces insulin resistance via the mTOR/Akt signaling pathway and an inflammatory response in adipose tissue
    Ruixin Sun, Yi Wu, Weihua Hou, Zujun Sun, Yu-Xiong Wang, Huanhuan Wei, Wei Mo, Min Yu · 2016 · Cellular Signalling
  24. mTOR inhibition in autosomal-dominant polycystic kidney disease (ADPKD): the question remains open
    Meg Jardine, Thaminda Liyanage, Erin Buxton, Vlado Perkovic · 2012 · Nephrology Dialysis Transplantation
  25. LMO3 promotes gastric cancer cell invasion and proliferation through Akt-mTOR and Akt-GSK3β signaling
    Yan-Song Qiu, Ningning Jiang, Yan Zhou, Kuai-Yun Yu, Hongyan Gong, Guangjun Liao · 2018 · International Journal of Molecular Medicine
  26. mTORC2: actin on your memory
    Sheena A. Josselyn, Paul W. Frankland · 2013 · Nature Neuroscience
  27. Rapamycin reduces kidney volume and delays the loss of renal function in a patient with autosomal-dominant polycystic kidney disease
    Ramón Peces, Carlos Peces, V. Perez-Duenas, Emilio Cuesta-López, Sebastián Azorín, Rafael Selgas · 2009 · Clinical Kidney Journal
  28. Rapamycin selectively reduces the association of transcripts containing complex 5′ UTRs with ribosomes in C4‐2B prostate cancer cells
    Lynn M. Opdenaker, Mary C. Farach‐Carson · 2009 · Journal of Cellular Biochemistry
  29. Everolimus vs. rapamycin for treating diabetic nephropathy in diabetic mouse model
    Lan Cheng, Jingli Chen, Xiaolu Mao · 2011 · Journal of Huazhong University of Science and Technology [Medical Sciences]
  30. Corrigendum to “Metformin suppresses adipogenesis through both AMP-activated protein kinase (AMPK)-dependent and AMPK-independent mechanisms” [Mol. Cell. Endocrinol. 440 15 January 2017 57–68]
    S.C. Chen, Rebecca A. Brooks, Jessica Houskeeper, Shaun Bremner, John Dunlop, Benoı̂t Viollet, Pamela J. Logan, Ian P. Salt, S. Faisal Ahmed, Stephen J. Yarwood · 2017 · Molecular and Cellular Endocrinology